WWW.KONF.X-PDF.RU
- , ,
 


Pages:     | 1 |   ...   | 2 | 3 ||

...

-- [ 4 ] --

100 .

3040 mmHg. 2 .

Nota bene! : (), FXa (). , .

1. .. - , . // . - 1996.

- 3. - . 5-15.

2. .. : 3 . / .. . 3. : , 2005. . 3. 416 .

3. .., .., .. . // .

2011. 4.

4. - () http://www.who.int

5. .. . : , 2000. 364 .

6. .. // . 1996. 1. . 1-15.

7. .. :

/ .. , .. , .. , ..

, .. , .. // .

. .. . 2004. .11, 3. . 10-15.

8. .. / .. // , . 2006. 2. . 24-34.

9. .., .., .. - : - :

. .: ; 2007. 1064 .

10. .., .., .. . / .. . : . . -, 2011. 138 . ISBN 978-5-7904-1176-2.

11. .. , / ..

[ .] // . 2010. . 4, . 2. .337.

12. .. . .

- . . . / ..

, .. , .. , .. , .. , .

. .. .: 2012. 20.

13. .. ( ):

/ .. , .. , . . .. / - . . . . , 2008, 72.

14.Al-Thani H, El-Menyar A, Asim M, Kiliyanni AS. Clinical Presentation, Management, and Outcomes of Deep Vein Thrombosis Based on Doppler Ultrasonography Examination // Angiology. 2015 Vol. 6.

15. Aleman MM, Walton BL, Byrnes JR, et al. Elevated prothrombin promotes venous, but not arterial, thrombosis in mice // ArteriosclerThrombVasc Biol.

2013 Vol. 33(8). P. 1829-36.

16. Ali N., Ayyub M., Khan SA. High prevalence of protein C, protein S, antithrombin deficiency, and Factor V Leiden mutation as a cause of hereditary thrombophilia in patients of venous thromboembolism and cerebrovascular accident // Pak J Med Sci. 2014. Vol. 30(6). P. 1323-6.

17. Ariens R.A.S., Lai T.-S., Weisel J.W. et al. Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms // Blood. 2002 Vol. 100. P.

743-754.

18. Ariens RA, Philippou H, Nagaswami C, Weisel JW, Lane DA, Grant PJ. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. // Blood. 2000 Vol. 96(3). P. 988Baglin T, Gray E, Greaves M, et al. British Committee for Standards in Haematology. Clinical guidelines for testing for heritable thrombophilia // Br J Haematol. 2010. Vol. 149. P. 209-20.

20. Bagoly Z, Koncz Z, et al., Factor XIII, clot structure, thrombosis // Thromb Res.

2012. Vol. 129(3). P. 382-7.

21. Balogh I, Szke G, Karpati L, et al. Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology in familial thrombophilia // Blood. 2000.

Vol. 96. P. 247986.

22. Balta G, Altay C, Gurgey A.PAI-1 gene 4G/5G genotype: A risk factor for thrombosis in vessels of internal organs // Am J Hematol. 2002. Vol. 71(2). P. 89-93.

23. Bates SM, Jaeschke R, Stevens SM, et al. Diagnosis of DVT: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines // Chest. 2012 Vol. 141 (suppl 2). P. e351Se418S.

24. Blohlvek J, Dytrych V, Linhart A.Pulmonary embolism, part I: Epidemiology, risk factors and risk stratification, pathophysiology, clinical presentation, diagnosis and nonthrombotic pulmonary embolism // ExpClinCardiol. 2013 Vol. 18(2). P. 129-38.

25. Bettmann MA, White RD, Woodard PK, et al. ACR Appropriateness Criteria Acute Chest Pain Suspected Pulmonary Embolism // J Thorac Imaging. 2012

Vol. 27. P. W28W31.

26. Brooks EG, Trotman W, Wadsworth MP, et al. Valves of the deep venous system: an overlooked risk factor // Blood. 2009. Vol. 114. P. 12761279.

27. Carter AM, Catto AJ, Kohler HP, et al. alpha-fibrinogen Thr312Ala polymorphism and venous thromboembolism // Blood. 2000. Vol. 96. P.

11779.

28. Cavezzi A., Labropoulos N, Partsch H, Ricci S. et al. Smith Duplex Ultrasound Investigation of the Veins in Chronic Venous Disease of the Lower Limbs UIP Consensus Document. Part II. Anatomy // Eur J VascEndovasc Surg. 2006 Vol. 31. P. 288299.

29. Chang J, Elam-Evans LD, Berg CJ, et al. Pregnancy-related mortality surveillance United States, 19911999 // MMWR SurveillSumm. 2003 Vol. 52. P. 18.

30. Chen XC, Xu MT, Zhou W, Han CL, Chen WQ. A meta-analysis of betafibrinogen gene-455G/A polymorphism and plasma fibrinogen level in Chinese cerebral infarction patients // Biomed Environ Sci. 2007. Vol. 20(5). P. 366Chen XD, Tian L, Li M, Jin W, et al. Relationship between endothelial cell protein C receptor gene 6936A/G polymorphisms and deep venous thrombosis // Chin Med J (Engl). 2011. Vol. 124(1). P. 72-5.

32. Chitsike RS, Rodger MA, Kovacs MJ, et al. Risk of post-thrombotic syndrome after subtherapeutic warfarin anticoagulation for a first unprovoked deep vein thrombosis: results from the REVERSE study // J ThrombHaemost. 2012 Vol.

10(10). P. 2039-44.

33. Christiansen SC, Cannegieter SC, Koster T, et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events // JAMA. 2005. Vol. 293. P. 2352 61.

34. Claassen L, Henneman L, Janssens AC et al. Using family history information to promote healthy lifestyles and prevent diseases; a discussion of the evidence // BMC Public Health. 2010 Vol. 13. P. 10:248.

35. Cochery-Nouvellon E, Mercier E, et al. Homozygosity for the C46T polymorphism of the F12 gene is a risk factor for venous thrombosis during the first pregnancy // J ThrombHaemost. 2007. Vol. 5(4). P. 700-7.

36. Cosmi B., Legnani C., Pengo V., et al. PROLONG Investigators (on behalf of FCSA, Italian Federation of Anticoagulation Clinics). The influence of factor V Leiden and G20210A prothrombin mutation on the presence of residual vein obstruction after idiopathic deep-vein thrombosis of the lower limbs // Thromb Haemost. 2013. Vol. 109(3). P. 510-6.

37. Coutance G, Cauderlier E, Ehtisham J, Hamon M, Hamon M. The prognostic value of markers of right ventricular dysfunction in pulmonary embolism: a metaanalysis // Crit Care. 2011 Vol. 15(2). P. R103.

38. Couturaud F., Leroyer C. Factors That Predict Risk of Thrombosis in Relatives of Patients With Unprovoked Venous Thromboembolism // CHEST. 2009 Vol.

136(6). P. 1537-1545.

39. Couturaud F., Leroyer C., Tromeur C. et al., Factors that predict thrombosis in relatives of patients with venous thromboembolism. // Blood. 2014. Vol.

124(13). P. 2124-30.

40. Cripe, L. D., Moore, K. D., Kane, W. H. Structure of the gene for human coagulation factor V // Biochemistry. 1992. Vol. 31. P. 3777-3785.

41. Currie G, Delles C. Proteinuria and its relation to cardiovascular disease // nt J NephrolRenovasc Dis. 2013 Vol. 7. P. 13-24.

42. Cushman M, Cornell A, Folsom AR, et al., Associations of the beta-fibrinogen Hae III and factor XIII Val34Leu gene variants with venous thrombosis // Thromb Res. 2007. Vol. 121(3). P. 339-45.

43. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C // ProcNatlAcadSci USA. 1993. Vol. 90. P. 1004-8.

44. Dahlbck B. Advances in understanding pathogenic mechanisms of thrombophilic disorders // Blood. 2008 Vol. 112(1). P. 19-27.

45. De Stefano V, Martinelli I, Mannucci P,et al., The Risk of Recurrent Deep Venous Thrombosis among Heterozygous Carriers of Both Factor V Leiden and the G20210A Prothrombin Mutation // N Engl J Med. 1999 Vol. 341. P.

801-806.

46. Dean L Smoking is an independent risk factor for VTE // J ThrombHaemost. 2009 Vol. 7. P. 1297-1303.

47. Degen, S. J. F., Schaefer, L. A., Jamison, C. S., et al., Characterization of the cDNA coding for mouse prothrombin and localization of the gene on mouse chromosome 2 // DNA Cell Biol. 1990. Vol. 9. P. 487-498.

48. Delluc A, Gouedard C, De Saint Martin L, et al., Incidence, risk factors and skin manifestations of post-thrombotic syndrome: a four-year follow-up of patients included in the EDITH study] // Rev Med Interne. 2010 Vol. 31(11). P.

729-34. Epub 2010 Sep 29.

49. Dennis J, Johnson CY, Adediran AS, et al., The endothelial protein C receptor (PROCR) Ser219Gly variant and risk of common thrombotic disorders: a HuGE review and meta-analysis of evidence from observational studies // Blood. 2012. Vol. 119(10). P. 2392-400.

50. Du GC, Zhang MC, Zhao JC. Catheter-directed thrombolysis plus anticoagulation versus anticoagulation alone in the treatment of proximal deep vein thrombosis a meta-analysis // Vasa. 2015 Vol. 44(3). P. 195-202.

51. Egeberg O. Inherited antithrombin deficiency causing thrombophilia // Thromb Diath Haemorrh. 1965. Vol. 13. P. 516530.

52. Emeis JJ. The control of tPA and PAI-1 secretion from the vessel wall // Vasc Med Rev. 1995. Vol. 6:153166.

53. Emmerich J, Rosendaal FR, Cattaneo M, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism pooled analysis of 8 casecontrol studies including 2310 cases and 3204 controls.

Study group for pooled-analysis in venous thromboembolism // ThrombHaemost.

2001. Vol. 86. P. 809-16.

54. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothormbin (20210GA) mutations in adults with a history of idiopathic VTE and their adult family members // Genet Med. 2011. Vol. 13. P. 67-76.

55. Farajzadeh M., Bargahi N., Poursadegh Zonouzi A. et al. Polymorphisms in thrombophilic genes are associated with deep venous thromboembolism in an Iranian population // Meta Gene. 2014. Vol. 2. P. 505-13.

56. Firkin F., Nandurkar H. Flying and thromboembolism //Australian Prescriber. 2009. Vol. 32 (6). P. 14850.

57. Galanaud J.P., Holcroft C.A., Rodger M.A., et al. Predictors of post-thrombotic syndrome in a population with a first deep vein thrombosis and no primary venous insufficiency. // J Thromb Haemost. 2013. Vol. 11(3). P. 474-80.

58. Geerts W.H., Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practiceguidelines (8th ed.) // Chest. 2008 Vol. 133. P. 381S -453S.

59. Ghaye B, Ghuysen A, Bruyere PJ, DOrio V, Dondelinger RF. Can CT pulmonary angiography allow assessment of severity and prognosis in patients presenting with pulmonary embolism? What the radiologist needs to know // Radiographics. 2006 Vol. 26. P. 2340.

60. Giannini M, Rollo HA, Maffei FHA: Role of duplex scanning in the diagnosis of asymptomatic lower-extremity deep venous thrombosis // J Vasc Br. 2005 Vol. 4(3). P. 290-6.

61. Gibson NS, Schellong SM, Kheir DY, et al. Safety and sensitivity of two ultrasound strategies in patients with clinically suspected deep venous thrombosis: a prospective management study // J Thromb Haemost. 2009 Vol.

7. P. 2035-2041.

62. Gohil R, Peck G, Sharma P. The genetics of venous thromboembolism. A metaanalysis involving approximately 120,000 cases and 180,000 controls // Thromb Haemost. 2009. Vol. 102(2). P. 360-70.

63. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER) // Lancet. 1999 Vol. 353. P. 13861389.

64. Gong XW, Yuan YD Meta-analysis of risk factors for all-cause mortality of pulmonary thromboembolism // Zhonghua Yi XueZaZhi. 2013 Vol. 27;93 (32). P. 2534-40.

65. Goodacre S, Sampson FC, Thomas S, van Beek E, Sutton A. Systematic review and meta-analysis of the diagnostic accuracy of ultrasonography for deep vein thrombosis // BMC Med Imaging. 2005 Vol. 5. P. 6.

66. Gu L., Liu W., Yan Y., Su L. et al. / Influence of the -fibrinogen-455G/A polymorphism on development of ischemic stroke and coronary heart disease // Thromb Res. 2014 Vol. 133 (6). P. 993-1005.

67. Guyatt, GH; Akl EA; Crowther M; et al. Executive Summary: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines // Chest. 2012 Vol.

141 (suppl 2). P. 7S47S.

68. Haeger K. Problems of acute deep venous thrombosis. I. The interpretation of signs and symptoms // Angiology. 1969 Vol. 20(4). P. 219-23.

69. Havig O. Deep vein thrombosis and pulmonary embolism. An autopsy study with multiple regression analysis of possible risk factors // ActaChirScand Suppl. 1977 Vol. 478. P. 1-120.

70. Heit J.A. Thrombophilia: common questions on laboratory assessment and management // Hematology Am SocHematol Educ. 2007. Vol. 1. P. 127 35.

71. Hirmerova J., Seidlerova J., Subrt I. The association of factor V Leiden with various clinical patterns of venous thromboembolism-the factor V Leiden paradox // QJM. 2014. Vol. 107(9). P. 715-20.

72. Hooper WC, El-Jamil M, Dilley A, et al. The relationship between the tissue plasminogen activator Alu I/D polymorphism and venous thromboembolism during pregnancy // Thromb Res. 2001. Vol. 102(1). P. 33-7.

73. Hornsby LB, Armstrong EM, Bellone JM, et al. Thrombophilia Screening. J Pharm Pract. 2014 Apr 16;27(3):253-259.

74. Huisman M.V., Klok FA, Karami Djurabi R, et al. Factor V Leiden is associated with more distal location of deep vein thrombosis of the leg // J Thromb Haemost.

2008 Vol. 6. P. 544545.

75. Humphries SE, Luong LA, Montgomery HE, et al. Gene-environment interaction in the determination of levels of plasma fibrinogen // ThrombHaemost. 1999. Vol. 82(2). P. 818-25.

76. Iorio A, Kearon C, Filippucci E, et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review // Arch Intern Med. 2010 Vol. 170:17101716.

77. Ireland HA, Cooper JA, Drenos F, et al. FVII, FVIIa, and downstream markers of extrinsic pathway activation differ by EPCR Ser219Gly variant in healthy men // ArteriosclerThrombVasc Biol. 2009 Vol. 29(11):1968-1974.

78. Jaff M.R., McMurtry M.S., Archer S.L., Cushman M., et al. American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; American Heart Association Council on Peripheral Vascular Disease; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association // Circulation. 2011. Vol. 123(16). P. 1788-830.

79. Jezovnik MK, PoredosP. Factors influencing the recanalisation rate of deep venous thrombosis // IntAngiol. 2012 Vol. 31(2). P. 169-75.

80. Jimnez D, DazG, Marn E et al The risk of recurrent venous thromboembolism in patients with unprovoked symptomatic deep vein thrombosis and asymptomatic pulmonary embolism // Thrombosis and Haemostasis. 2006 Vol. 95 3. P. 562-566.

81. Johnson S A., Stevens SM., Woller SC. et al., Risk of Deep Vein Thrombosis Following a Single Negative Whole-Leg Compression Ultrasound // JAMA. 2010 Vol. 303. P. 438-445, 454-455.

82. Kahn SR, Kearon C, Julian JA, et al. Predictors of the post-thrombotic syndrome during long-term treatment of proximal deep vein thrombosis // J ThrombHaemost. 2005 Vol. 3(4). P. 718-723.

83. Kahn SR, S Solymoss S, Lamping DL, Abenhaim L, Long-term Outcomes After Deep Vein Thrombosis: Postphlebitic Syndrome and Quality of Life. // J Gen Intern Med. 2000 Vol. 15(6). P. 425429.

84. Kahn SR, Shrier I, Julian JA, Ducruet T, et al. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis // Ann Intern Med. 2008 Vol. 149. P. 698707.

85. Kahn SR. How I treat postthrombotic syndrome. Blood 2009 Vol. 114. P.

4624-31.

86. Kain K, Blaxill JM, Catto AJ, Grant PJ. Increased fibrinogen levels among South Asians versus Whites in the United Kingdom are not explained by common polymorphisms // Am J Epidemiol. 2002. Vol. 156. P. 1749.

87. Kalb B, Sharma P, Tigges S, Ray GL, et al., MR imaging of pulmonary embolism: diagnostic accuracy of contrast-enhanced 3D MR pulmonary angiography, contrast-enhanced low-flip angle 3D GRE, and nonenhanced freeinduction FISP sequences // Radiology. 2012 Vol. 263(1). P. 271-8.

88. Kanaji T., Okamura T., Osaki K., Kuroiwa M., et al., A common genetic polymorphism (46 C to T substitution) in the 5'-untranslated region of the coagulation factor XII gene is associated with low translation efficiency and decrease in plasma factor XII level // Blood. 1998. Vol.15; 91(6). P. 2010-4.

89. Kearon C, Kahn SR, Agnelli G, Goldhaber S, et al., 2008 Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) // Chest. 2008 Vol.

133(6 Suppl). P. 454S-545S.

90. Kolbach D, Sandbrink M, Hamulyak K, Neumann H, and Prins M. Nonpharmaceutical measures for prevention of post-thrombotic syndrome // Cochrane Database Syst Rev. 2004 Vol. (1). P. CD004174.

91. Kolbach DN, Veraart JC, Hamulyk K, et al. Recurrent leg ulcers in a young man with hyperhomocysteinemia, factor V Leiden and impaired fibrinolysis // ActaDermVenereol. 2002 Vol. 82(1). P. 52-4.

92.Kovac M, Mitic G, Mikovic Z, et al. Type and location of venous thromboembolism in carriers of Factor V Leiden or prothrombin G20210A mutation versus patients with no mutation. Clin Appl Thromb Hemost. 2010 Feb;16(1):66-70.

93. Labropoulos N, Waggoner T, Sammis W, et al. The effect of venous thrombus location and extent on the development of post-thrombotic signs and symptom // J Vasc Surg. 2008 Vol. 48. P. 407.

94. Labropoulos N, Gasparis AP, Tassiopoulos AK. Prospective evaluation of the clinical deterioration in post-thrombotic limbs // J Vasc Surg. 2009 Vol.

50(4). P. 826-30.

95. Labropoulos N, Jen J, Jen H, et al. Recurrent deep vein thrombosis: long-term incidence and natural history // Ann Surg. 2010 Vol. 251(4). P. 749-53.

96. Ladenvall P, Johansson L, Jansson JH, et al. Tissue-type plasminogen activator C/T enhancer polymorphism is associated with a first myocardial infarction // ThrombHaemost. 2002. Vol. 87(1). P. 105-9.

97. Lancellotti, S., De Cristofaro, R. Congenital prothrombin deficiency // Semin.

Thromb. Hemost. 2009. Vol. 35. P. 367-381.

98. Lee IH, Chung SI, Lee SY. Effects of Val34Leu and Val35Leu polymorphism on the enzyme activity of the coagulation factor XIII-A // Exp Mol Med. 2002. Vol. 34(5). P. 385-90.

99. Lidegaard, Milsom I, Geirsson RT, Skjeldestad FE. Hormonal contraception and venous thromboembolism // ActaObstetGynecol Scand. 2012 Vol.

91(7). P. 769-78.

100.Lijfering W, Middeldorp S, Veeger N, et al. Received Risk of Recurrent Venous Thrombosis in Homozygous Carriers and Double Heterozygous Carriers of Factor V Leiden and Prothrombin G20210A //Circulation. 2010 Vol.

20;121(15). P. 1706-12.

101.Lindqvist PG, Svensson PJ, Marsaal K, et al. Activated protein C resistance (FV:Q506) and pregnancy // ThrombHaemost. 1999. Vol. 81. P. 532537.

102.Lund FL, Diener L, Ericsson JLE. Postmortem intraosseous phlebography as an aid in studies of venous thromboembolism: with application on a geriatric clientele // Angiology. 1969. Vol. 20. P. 155-176.

103.Mahmoudi B.K., Gansevoort R.T., Veeger NJGM, et al. Microalbuminuria and risk of venous thromboembolism // JAMA. 2009 Vol. 301. P. 1790-1797.

104.Martinelli I, Battaglioli T, Razzari C, Mannucci PM: Type and location of venous thromboembolism in patients with factor V Leiden or prothrombin G20210A and in those with no thrombophilia // J Thromb Haemost. 2007 Vol. 5. P. 98Martinelli I, De Stefano V, Mannucci PM. Inherited risk factors for venous thromboembolism // Nat Rev Cardiol. 2014.

106.Martinelli I., Battaglioli T., Tosetto A., et al. Prothrombin A19911G polymorphism and the risk of venous thromboembolism // J ThrombHaemost. 2006. Vol. 4. P. 25826.

107.Masotti L., Righini M., Vuilleumier N., et al. Prognostic stratification of acute pulmonary embolism: Focus on clinical aspects, imaging, and biomarkers // Vasc Health Risk Manag. 2009 Vol. 5. P. 567575.

108.McColl MD, Ellison J, Greer IA, et al. Prevalence of the post-thrombotic syndrome in young women with previous venous thromboembolism // Br J Haematol. 2000 Vol. 108. P. 2724.

109.Medina P, Navarro S, Estells A, Espaa F. Polymorphisms in the endothelial protein C receptor gene and thrombophilia // ThrombHaemost. 2007. Vol.

98(3). P. 564-9.

110.Medina P, Navarro S, Estells A, et al. Contribution of polymorphisms in the endothelial protein C receptor gene to soluble endothelial protein C receptor and circulating activated protein C levels, and thrombotic risk // Thromb Haemost. 2004. Vol. 91(5). P. 905-11.

111.Medina P., Navarro S., Bonet E., et al. Functional analysis of two haplotypes of the human endothelial protein C receptor gene // Arterioscler Thromb Vasc Biol.

2014. Vol. 34(3). P. 684-90.

112.Meissner M.H., Zierler BK, Bergelin RO, et al. Coagulation, fibrinolysis, and recanalization after acute deep venous thrombosis // J Vasc Surg. 2002 Vol.

35(2). P. 278-85.

113.Meissner, M.H., Eklof, B., Smith, P.C., Dalsing, M.C., DePalma, R.G., Gloviczki, P. et al. Secondary chronic venous disorders // J Vasc Surg. 2007 Vol. 46. P. 68S83S

114.Miles JS, Miletich JP, Goldhaber SZ, et al. G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism// J Am CollCardiol. 2001. Vol. 37. P. 2158.

115.Nicolaides A., Hull R.D., Fareed J. Prevention and treatment of venous thromboembolism: international consensus statement (guidelines according to scientific evidence) // ClinApplThrombHemost. 2013. Vol. 19(2). P. 116-8.

116.Nizankowska-Mogilnicka E., L. Adamek, P. Grzanka, et al. Genetic polymorphisms associated with acute pulmonary embolism and deep venous thrombosis // EurRespir J. 2003 Vol. 21 (1). P. 25-30.

117.Noboa S., Le Gal G., Lacut K., Mercier B., et al. Family history as a risk factor for venous thromboembolism // Thromb Res. 2008 Vol. 122(5). P.

624-9.

118.Oguzulgen IK, Ekim N, Erkekol FO, et al. Is tissue-plasminogen activator gene polymorphism a risk factor for venous thromboembolism in every population // Thromb Thrombolysis. 2005. Vol. 19(1). P. 61-3.

119.Palareti G, Cosmi B, Legnani C, et al., PROLONG Investigators. D-dimer testing to determine the duration of anticoagulation therapy // N Engl J Med. 2006 Vol. 355. P. 17801789.

120.Pavlidis AN, Kallistratos MS, Karamasis et al. Diagnosis and risk stratification in acute pulmonary embolism: the role of echocardiography // RevCardiovasc Med. 2013 Vol. 14(1). P. 56-65.

121.Pomero F., Ageno W., Serraino C., Borretta V. et al. The role of inherited thrombophilia in patients with isolated pulmonary embolism: a systematic review and a meta-analysis of the literature. // Thromb Res. 2014. Vol. 134(1). P.

84-9.

122.Prandoni P, Kahn SR. Post-thrombotic syndrome: prevalence, prognostication and need for progress // Br J Haematol. 2009 Vol. 145(3). P. 286-95.

123.Prandoni P, Lensing AW, CogoA, et al. The long-term clinical course of acute deep venous thrombosis // Ann Intern Med. 1996 Vol. 1. P. 1-7.

124.Prandoni P, Noventa F, Ghirarduzzi A et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients // Haematologica. 2007. Vol. 92. P. 199205.

125.Prandoni P, Piovella C, Spiezia L, et al. Optimal duration of anticoagulation in patients with venous thromboembolism // Indian J Med Res. 2011 Vol.

134(1). P. 15-21.

126.Prandoni P, Prins MH, Lensing AW, et al., AESOPUS Investigators. Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial // Ann Intern Med. 2009 Vol. 150. P. 577585.

127.Pusks A, Balogh Z, Hadadi L, Imre M, et al. Spontaneous recanalization in deep venous thrombosis: a prospective duplex ultrasound study // Int Angiol. 2007 Vol. 26(1). P. 53-63.

128.Qu D, Wang Y, Song Y, Esmon NL, Esmon CT. The Ser219Gly dimorphism of the endothelial protein C receptor contributes to the higher soluble protein levels observed in individuals with the A3 haplotype // ThrombHaemost. 2006.

Vol. 4. P. 229-235.

129.Quinlan DJ, Eikelboom JW, Dahl OE, et al. Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery // J ThrombHaemost. 2007 Vol. 5. P. 1438-43.

130.Rasighaemi P, Kazemi A, Ala F, Jazebi M, Razmkhah F Association of FXII 5UTR 46CT polymorphism with FXII activity and risk of thrombotic disease // Turkish Journal of Hematology. 2010. Vol. 27. P. 15-19.

131.Rasmussen-Torvik LJ, Cushman M, Tsai MY, Zhang Y et al. The association of alpha-fibrinogen Thr312Ala polymorphism and venous thromboembolism in the LITE study // Thromb Res. 2007. Vol. 121(1). P. 1-7.

132.Red G, Tssies D, Espinosa G, Monteagudo J,et al. Factor XIII-A subunit Val34Leu polymorphism is associated with the risk of thrombosis in patients with antiphospholipid antibodies and high fibrinogen levels // ThrombHaemost. 2009. Vol. 101(2). P. 312-6.

133.Rosendaal FR, Reitsma P H Genetics of venous thrombosis // Journal of Thrombosis and Haemostasis. 2009. Vol. 7 (Suppl. 1). P. 301304.

134.Saposnik B, Reny JL, Gaussem P, et al. A haplotype of the EPCR gene is associated with increased plasma levels of sEPCR and is a candidate risk factor for thrombosis // Blood. 2004. Vol. 103(4). P. 1311-8.

135.Schulman S., Thrombophilia and location of venous thromboembolism // J Thromb Haemost. 2007 Vol. 5. P. 21512152.

136.Scott J, Trotter T. Primary care and genetics and genomics // Pediatrics. 2013 Dec; 132(Suppl 3). P. S231-7.

137.Segal JB, Brotman DJ, Necochea AJ, et al. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review // JAMA. 2009. Vol.

301. P. 247285.

138.Severinsen M. T., Kristensen S. R., Johnsen S. P., Dethlefsen C. et al, Smoking and venous thromboembolism: a Danish follow-up study // J ThrombHaemost. 2009 Vol. 7(8). P. 1297-303.

139.Shbaklo H, Holcroft CA, Kahn SR. Levels of inflammatory markers and the development of the post-thrombotic syndrome // ThrombHaemost. 2009 Vol.

101. P. 505-12.

140.Simone B, De Stefano V, Leoncini E, Zacho J, et al. Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolatereductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls // Eur J Epidemiol. 2013 Vol. 28(8). P. 621-47.

141.Singh H, Masuda EM. Comparing short-term outcomes of femoral-popliteal and iliofemoral deep venous thrombosis: early lysis and development of reflux // Ann Vasc Surg. 2005 Vol. 19. P. 7479.

142.Sode BF, Allin KH, Dahl M, et al. Risk of venous thromboembolism and myocardial infarction associated with factor V Leiden and prothrombin mutations and blood type // CMAJ. 2013 Vol. 185(5). P. E229-37.

143.Spencer FA, Lessard D, Emery C, Reed G, Goldberg RJ. Venous thromboembolism in the outpatient setting // Arch Intern Med. 2007 Vol. 167.

P. 1471-5.

144.Spiezia L, Campello E, Giolo E, et al. Thrombophilia and the risk of postthrombotic syndrome: retrospective cohort observation // J ThrombHaemost. 2010 Vol. 8. P. 2113.

145.Spiezia L, Tormene D, Pesavento R, et al. Thrombophilia as a predictor of persistent residual vein thrombosis // Haematologica. 2008 Vol. 93(3). P.

479-80.

146.Stain M, Schonauer V, Minar E, et al. The post-thrombotic syndrome: risk factors and impact on the course of thrombotic disease // J ThrombHaemost. 2005 Vol. 3(12). P. 2671-2676.

147.Standeven KF, Grant PJ, Carter AM, et al. Functional analysis of the fibrinogen Aalpha Thr312Ala polymorphism: effects on fibrin structure and function // Circulation. 2003. Vol. 107. P. 232630.

148.Stein PD, Woodard PK, Weg JG, et al. Diagnostic pathways in acute pulmonary embolism: recommendations of the PIOPED II investigators // Am J Med. 2006

Vol. 119. P. 10481055.

149.Stephen R, Jolly SE, Nally JV et al. Albuminuria: When urine predicts kidney and cardiovascular disease // Cleve Clin J Med. 2014 Vol. 81(1). P. 41-50.

150.Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis // N Engl J Med. 1994. Vol. 330. P. 517522.

151.Ten Cate-Hoek A.J., Bouman A.C., Joore M.A., Prins M. IDEAL DVT trial investigators. The IDEAL DVT study, individualised duration elastic compression therapy against long-term duration of therapy for the prevention of post-thrombotic syndrome: protocol of a randomised controlled trial. // BMJ Open. 2014. Vol. 4(9). P. e005265.

152.Ten Wolde M, Sohne M, Quak E, et al. Prognostic value of echocardiographically assessed right ventricular dysfunction in patients with pulmonary embolism // Arch Intern Med. 2004. Vol. 164. P. 16851689.

153.Tick, L.W., Kramer, M.H., Rosendaal, F.R., Faber, et al. Risk factors for postthrombotic syndrome in patients with a first deep venous thrombosis // Thrombosis and Haemostasis. 2008 Vol. 6. P. 20752081.

154.Tiedje V, Dunkler D, Ay C, Horvath B, et al. The role of fibrinogen plasma levels, the -455GA fibrinogen and the factor XIII A subunit (FXIII-A) Val34Leu polymorphism in cancer-associated venous thrombosis // ThrombHaemost. 2011. Vol. 106(5). P. 908-13.

155.Tjarnlund-Wolf A, Hultman K, Curtis MA,et al. Allelic imbalance of tissue-type plasminogen activator (t-PA) gene expression in human brain tissue // ThrombHaemost. 2011. Vol. 105 (6). P. 945-53.

156.Torbicki A, Perrier A, Konstantinides S, et al. Guidelines on the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology // Eur Heart J. 2008. Vol. 29. P. 22762315.

157.Tzoran I, Saharov G, Brenner B, Delsart D et al. Silent pulmonary embolism in patients with proximal deep vein thrombosis in the lower limbs // J ThrombHaemost. 2012 Vol. 10(4). P. 564-71.

158.van 't Hooft FM, von Bahr SJ, Silveira A, et al. Two common, functional polymorphisms in the promoter region of the beta-fibrinogen gene contribute to regulation of plasma fibrinogen concentration // ArteriosclerThrombVasc Biol. 1999. Vol. 19(12). P. 3063-70.

159.Van de Wouwer M, Collen D, Conway EM. Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation // Arteriosclerosis, Thrombosis, and Vascular Biology. 2004. Vol. 24. P. 13741383.

160.Van Dongen CJ, Prandoni P, Frulla M, et al. Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome // J ThrombHaemost. 2005 Vol. 3. P. 939942.

161.van Hylckama Vlieg A, Komanasin N, Ariens RA, et al. Factor XIII Val34Leu polymorphism, factor XIII antigen levels and activity and the risk of deep venous thrombosis // Br J Haematol. 2002 Vol. 119(1). P. 169175.

162.van Rij AM, Hill G, Krysa J, Dutton S, et al. Prospective study of natural history of deep vein thrombosis: early predictors of poor late outcomes // Ann Vasc Surg.

2013 Vol. 27(7). P. 924-31.

163.van Schouwenburg I.M., Bakhtawar K. Mahmoodi et al. Elevated albuminuria associated with increased risk of recurrent venous thromboembolism: results of a population-based cohort study British Journal of HaematologyVolume 156, Issue 5, pages 667671, March 2012

164.van Stralen KJ, Doggen CJ, Bezemer ID, et al. Mechanisms of the factor V Leiden paradox // ArteriosclerThrombVasc Biol. 2008. Vol. 28. P. 1872.

165.Vasquez MA, Rabe E, McLafferty RB, et al. American Venous Forum Ad Hoc Outcomes Working Group. Revision of the venous clinical severity score: venous outcomes consensus statement: special communication of the American Venous Forum Ad Hoc Outcomes Working Group // J Vasc Surg. 2010 Vol. 52(5). P. 1387-96.

166.Vedantham S. Valvular dysfunction and venous obstruction in the postthrombotic syndrome // Thromb Res. 2009 Vol. 123(4). P. S62-5.

167.Verhovsek M, Douketis JD, Yi Q, et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism // Ann Intern Med. 2008 Vol. 149. P. 481490, W94.

168.Villoutreix BO, Blom AM, Dahlback B. Structural prediction and analysis of endothelial cell protein C/activated protein C receptor // Protein Eng. 1999. Vol. 12. P. 833-840.

169.Virchow R LK. Translation in Matzdorff AC, Bell WR, trans, editor. Thrombosis and embolie (18461856). Canton, MA: Science History Publications; 1998.

Originally published in German as Thrombose und Embolie. Gefssentzndung und septischeInfektion, GesammelteAbhandlungenzurwissenschaftlichenMedici n. Frankfurtam Main: Von Meidinger&Sohn. 1856. P. 219732.

170.Virchow RLK. Phlogose und thromboseimGefsystem // Gesammelte

Abhandlungzur Wissenchaftlichen Medizin. Franksfurt, Germany:

Staatsdruckerei. 1856.

171.Volpe M. Microalbuminuria screening in patients with hypertension:

Recommendations for clinical practice // Int J ClinPract. 2008 Vol. 62 (1). P. 97108.

172.Wakefield TW, Myers DD, Henke PK. Mechanisms of Venous Thrombosis and Resolution // Arteriosclerosis, Thrombosis, and Vascular Biology. 2008. Vol.

28. P. 387.

173.Wells PS, Rodger M. Diagnosis of pulmonary embolism: when is imaging needed? // Clin Chest Med. 2003 Vol. 24(1). P. 13-28.

174.Wichers I.M., Tanck M.W., Meijers J.C., et al. Assessment of coagulation and fibrinolysis in families with unexplained thrombophilia // Thromb Haemost. 2009. Vol. 101(3). P. 465-70.

175.Wik HS, Jacobsen AF, Sandvik L, Sandset PM. Prevalence and predictors for post-thrombotic syndrome 3 to 16 years after pregnancy-related venous thrombosis: a population-based, cross-sectional, case-control study // J ThrombHaemost. 2012 Vol. 10(5). P. 840-7.

176.Wolpert C M, Speer MC. Harnessing the power of the pedigree // J Midwifery Women's Health. 2005 Vol. 50. P. 189-196.

177.Wong P., Baglin T. Epidemiology, risk factors and sequelae of venous thromboembolism // Phlebology 2012. Vol. 27(Suppl 2). P. 211.

178.Worsley DF, Alavi A. Comprehensive analysis of the results of the PIOPED Study. Prospective Investigation of Pulmonary Embolism Diagnosis Study // J Nucl Med. 1995 Vol. 36(12). P. 2380-7.

179.Yamaki T, Hamahata A, Soejima K, et al. Factors predicting development of post-thrombotic syndrome in patients with a first episode of deep vein thrombosis: preliminary report // Eur J VascEndovasc Surg. 2011 Vol. 41(1).

P. 126-33.

180.Zhan M, Zhou Y, Han Z. Plasminogen activator inhibitor-1 4G/5G gene polymorphism in patients with myocardial or cerebrovascular infarction in Tianjin, China // Chin Med J (Engl). 2003 Vol. 116(11). P. 1707-10.

181.Zhu T, Martinez I, Emmerich J. Venous thromboembolism: risk factors for recurrence // ArteriosclerThrombVasc Biol. 2009 Vol. 29(3). P. 298-310.

182.Zller B, Ohlsson H, Sundquist J et al. Family history of venous thromboembolism (VTE) and risk of recurrent hospitalization for VTE: a nationwide family study in Sweden // J ThrombHaemost. 2013.

183.Zutt M, Krger U, Rosenberger A, et al. Thrombophilia in patients with chronic venous leg ulcers-a study on patients with or without post-thrombotic syndrome // J Eur Acad Dermatol Venereol. 2011 Vol. 11.



Pages:     | 1 |   ...   | 2 | 3 ||

:

633.34:551. 11.00.09 , , : , , 2015 . . ...

- - 03.02.06 , .. 2015 ...

: 03.02.08 , .. 2015 , . .. 5 1. . 19...

- 06.02.10 , ; 06.02.08 , . ...

, 03.02.02 2015 1. ...

, 03.02.08 : ...

03.02.08 : , .. -2015 .. 1 .. 1.1. 1.2. ...

06.02.02 , , , ...

03.02.10. : , 2015 . 1 1.1. ...

, - 06.01.05 ...

(SORBUS L.) 03.02.01 : ..., ... .. 2014 .. 4 1. .. 8 ...

03.02.02 : , 2014 1 2 2.1 2.2 ...

_ 14.01.07 : ...

- - 03.02.06 , .. 2015 ...

(OVIBOS MOSCHATUS ZIMMERMANN, 1780) 03.02.08 : . . ., . . 2015 .. 1. -...

- 03.02.03 ...

14.01.07 : , ...

PARAPHOMA SP. 1.46 : 03.02.12 : .. -...

14.01.01 :...

ECHINOTHRIPS AMERICANUS MORGAN Ȩ - 06.01.07 : , , ...







 
<<     |    
2016 www.konf.x-pdf.ru - - , ,

, .
, , , , 1-2 .